A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Patients with diabetic DED can experience inflammatory biomarker reductions and sign and symptom improvements with topical insulin.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...

Over 66% of U.S. adults use at least one prescription drug, according to data gathered by the Health Policy Institute at ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Recent price cuts by major insulin manufacturers may appear to address affordability challenges, but they primarily target older insulin drugs nearing patent expiration. This tactic, coupled with the ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Figures exchanged for the six players remaining in salary arbitration and their 2024 salaries, as obtained by The Associated Press from player and management sources: ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two ...

Engulfing Bearish 15 69 Jan 29, 2025 12:15 ...